Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Open accessPublished version of a preprint
The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index; 26 of the 67 sources its claims cite were checked for support.
Abstract
Multiple clinical trials targeting the gut microbiome are being conducted to optimize treatment outcomes for immune checkpoint blockade (ICB). To improve the success of these interventions, understanding gut microbiome changes during ICB is urgently needed. Here through longitudinal microbiome profiling of 175 patients treated with ICB for advanced melanoma, we show that several microbial species-level genome bins (SGBs) and pathways exhibit distinct patterns from baseline in patients achieving progression-free survival (PFS) of 12 months or longer (PFS ≥12) versus patients with PFS shorter than 12 months (PFS <12). Out of 99 SGBs that could discriminate between these two groups, 20 were differentially abundant only at baseline, while 42 were differentially abundant only after treatment initiation. We identify five and four SGBs that had consistently higher abundances in patients with PFS ≥12 and <12 months, respectively. Constructing a log ratio of these SGBs, we find an association with overall survival. Finally, we find different microbial dynamics in different clinical contexts including the type of ICB regimen, development of immune-related adverse events and concomitant medication use. Insights into the longitudinal dynamics of the gut microbiome in association with host factors and treatment regimens will be critical for guiding rational microbiome-targeted therapies aimed at enhancing ICB efficacy.
Overview
CoChat Summary
TL;DR
Longitudinal shotgun metagenomic profiling of 175 patients with advanced melanoma receiving immune checkpoint blockade identified microbial species and pathways whose trajectories differ between patients with PFS ≥12 versus <12 months. A baseline balance of consistently higher taxa predicted PFS12 and overall survival, while microbial dynamics varied by ICB regimen, colitis and PPI use.
Key findings
- Among 99 SGBs discriminating PFS ≥12 from PFS <12 months at ≥1 visit, 20 differed only at baseline, 42 only after treatment initiation, and 5 versus 4 SGBs remained consistently higher in PFS ≥12 and PFS <12 months, respectively.
- A balance of the 5 PFS ≥12-associated and 4 PFS <12-associated SGBs discriminated PFS12 at T0–T2 (two-sided Wilcoxon P = 0.00085, 0.0007, 0.0005; T3 P = 0.1) with AUCs of 0.659 ± 0.092, 0.666 ± 0.091, 0.739 ± 0.118 and 0.655 ± 0.129; above-median patients had longer OS (35.4 versus 28.4 months; HR 1.669, P = 0.035).
- Clinical context altered dynamics: 28 associations were shared between monotherapy and combination therapy, with 6 SGBs showing opposite patterns; a colitis-associated balance predicted colitis at baseline (P = 0.00055; AUC 0.723 ± 0.121), and PPI users on monotherapy shared 33 associations with nonusers.
- Patients with PFS ≥12 months showed higher SCFA-related pathways and a polyamine synthesis pathway after baseline, whereas patients with PFS <12 months showed higher menaquinol synthesis pathways at baseline and early treatment.
Methods
- Multicenter cohort of 175 patients with unresectable stage 3/4 cutaneous melanoma from five cohorts in the Netherlands, UK and Spain; 117 (67%) received anti-PD-1 monotherapy and 58 (33%) anti-PD-1/CTLA-4 combination therapy. Fecal shotgun metagenomics was performed at baseline and three subsequent visits over 12 weeks, yielding 408 samples from 175 patients after filtering.
- Taxonomic and functional profiling used MetaPhlAn4 and MetaCyc; a Bayesian multinomial logistic normal regression model (Pibble/fido) with higher-order interactions modeled linear microbial trajectories by PFS ≥12 versus <12 months and clinical moderators (monotherapy versus combination, colitis, PPI use), adjusting for confounders; post hoc contrasts used 90% Bayesian confidence level.
- Balances were computed as log ratios between selected SGB sets; associations with OS/PFS used Cox proportional hazards and Kaplan–Meier analysis, and the main balance was tested in six independent melanoma cohorts.
Limitations
- Stated by the paper: microbial dynamics were simplified to linear trajectories; comparability with previous studies using different taxonomic databases is limited; and smaller patient numbers for some post hoc comparisons limit generalizability.
- Evident from the text: the study is observational and does not establish causality; validation in independent cohorts was constrained by small sample sizes and heterogeneity, with only one reasonably large cohort (N = 112) showing discrimination for PFS12 and one small cohort (N = 27) predicting OS.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







![Extended Data Fig. 3 Extended longitudinal balance. The extended balance has 12 SGBs in the numerator (A. butyriciproducens [SGB14993 group], I. bartlettii [SGB6140], D. sp AF24 7LB [SGB4571], L. gasseri [SGB7038 group], L. celerecrescens [SGB4868], R. sp NSJ 71 [SGB4290], GGB9640 [SGB15115], E. rectale [SGB4933 group], E. entriosum [SGB5045], E. sp AM28 29 [SGB6796 group], Clostridium sp AF15 49 [SGB5111], and A. bouchesdurhonensis [SGB17152]) and 9 SGBs in the denominator (R. lactatiformans [SGB15271], R. unclassified [SGB15265 group], P. copri clade A [SGB1626], GGB1420 [SGB1957], Gemmiger [SGB15299], B. obeum [SGB4809], Clostridiales unclassified [SGB15145], P. vulgatus [SGB1814], and B. clarus [SGB1832]). Panel (A) balance’s ability to discriminate between patients with PFS ≥ 12 (n = 83; n0 = 62; n1 = 77; n2 = 38; n3 = 30) and PFS < 12 (n = 92; n0 = 74; n1 = 69; n2 = 34; n3 = 24) months across study visits. Boxplots represent minima, Q1, Q2, Q3, and maxima. Panel (B) the balance’s predictive ability expressed as the Area Under the Curve (AUC) computed from 100 times repeated five-fold cross-validation (CV). Each line shows, for each study visit, the average across the 100 repeated five-fold CVs with the shaded area representing the 95% confidence interval. Panel (C) Kaplan–Meier curves and multivariable Cox regression analysis of overall survival in 146 patients at baseline (one patient was removed due to missingness in the included predictor variables) according to high (above median) and low (below median) values of the balance after adjusting for age, sex, BMI, previous therapy, PPI and antibiotic use.](https://figures.cochat.ai/paper-figures/043339c832fa41a2b4023d0746660ca9/longitudinal-gut-microbiome-changes-in-immune-checkpoint-blockade-treated-figure-8.jpg)







Verification
Claims the paper makes
13 Valid · 1 Not valid · 18 Not checked · 99 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Three of these species have recently been associated with response in two new studies utilizing MetaPhlAn4, one meta-analysis21 and one phase 1 FMT trial of ICB-naive patients22.”
§ Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma > Results > Cohort characteristics
What the sources say
- Partly supportedcites [21] Thomas, A. M. et al. Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy. Nat. Rev. Clin. Oncol. 20, 583–603 (2023). sourceExperimental — accuracy not yet measured
Our copy does contain a meta-analysis that used MetaPhlAn 4 and linked species to ICI response: in 'GOMS and prediction of response to ICIs' the authors state they 'performed a meta-analysis and mega-analysis of stools taxonomically profiled with MetaPhlAn 4' over 12 cohorts / 761 patients, naming responder taxa (A. muciniphila SGB9226, Roseburia hominis SGB4936, Faecalibacterium SGB15346, F. prausnitzii, E. rectale, and in the meta-analysis arm A. shahii, B. bifidum, B. adolescentis, P. copri SGB16). However, the specific quantification 'three of the five PFS ≥12-associated species' is not in our copy — the only PFS>12-month species association reported is A. muciniphila prevalence in one second-line nivolumab RCC cohort (ref. 26), with no enumerated set of five such species. Nor does our copy describe a phase 1 FMT trial in ICB-naive patients; its FMT discussion covers mouse models and the melanoma trial reverting anti-PD-1 resistance (Davar et al., ref. 128). Those two elements are therefore attributed here but not supported by this source. (LLM, conf=0.72)
- Not checked yetcites [22] Routy, B. et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat. Med. 29, 2121–2132 (2023). source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“We next tested the generalizability of the balance described in Fig. 2a by computing it for patients from six independent melanoma cohorts5,7–10,12. Despite small sample sizes and large heterogeneity in terms of DNA isolation protocols and sequencing platforms (Supplementary Table 6), this analysis showed that the balance achieves a comparable AUC in several of the independent cohorts (Extended”
§ Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma > Results > Cohort characteristics
What the sources say
- Supportedcites [5] McCulloch, J. A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat. Med. 28, 545–556 (2022). source
The citation is attached to the identification of melanoma cohorts, not to the citing authors’ subsequent balance and AUC analysis. The Extended Data passage identifies a Pittsburgh cohort of PD-1-treated melanoma patients, supporting this paper’s use as a cohort source. (LLM, conf=0.90)
- Supportedcites [7] Spencer, C. N. et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374, 1632–1640 (2021). source
The citation appears in the list identifying the six melanoma cohorts, rather than after the citing authors’ statement about the balance’s AUC. The source’s Abstract describes its melanoma patient cohort and gut-microbiome profiling, supporting its identification as one of the cohorts used in that analysis. (LLM, conf=0.88)
- Supportedcites [8] Peters, B. A. et al. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. Genome Med. 11, 61 (2019). source
The citation identifies one of the melanoma cohorts used in the citing authors’ analysis. The Methods > Patients section describes a cohort of 27 melanoma patients recruited before immunotherapy. The cross-cohort balance and AUC are results of the citing authors’ analysis, not findings attributed to this source. (LLM, conf=0.91)
- Supportedcites [9] Gopalakrishnan, V. et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018). source
The study description reports a cohort of 112 patients with metastatic melanoma whose microbiomes were sampled during anti-PD-1 treatment. The citation identifies one of the melanoma cohorts used in the citing authors’ analysis; the comparable AUC is a result of that analysis, not a finding attributed to this source. (LLM, conf=0.91)
- Supportedcites [10] Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018). source
The citation identifies one of the independent melanoma cohorts used in the citing authors’ analysis. The source describes stool samples from 42 metastatic melanoma patients collected before treatment (Abstract). The balance calculation, cross-cohort AUC, and protocol heterogeneity are results of the citing authors’ analysis, not findings attributed to this source. (LLM, conf=0.91)
- Supportedcites [12] Frankel, A. E. et al. Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia 19, 848–855 (2017). source
The citation identifies one of the melanoma cohorts used in the citing authors’ six-cohort analysis; it does not attribute that analysis or its AUC finding to this source. The source’s Results describe 39 metastatic melanoma patients with pretreatment fecal samples and immunotherapy outcomes, and its Metagenomic Shotgun Sequencing and Analysis section describes sequencing those samples. Together, those passages support its identification as a melanoma cohort. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“an overall signature resembling the gut microbiome of patients with inflammatory bowel disease20”
§ Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma > Results > The clinical context influences abundance patterns
What the sources say
- Partly supportedcites [20] Imhann, F. et al. Proton pump inhibitors affect the gut microbiome. Gut 65, 740–748 (2016). sourceExperimental — accuracy not yet measured
The Discussion/Conclusions (p. of our copy, 'Conclusions') states that prominent microbiome studies in obesity, IBD and NAFLD report changes attributed to those conditions which 'we show are also associated with PPI use' (citing Morgan et al. 2012, ref 17, on IBD dysbiosis), and that some such effects 'should rather have been attributed to the use of PPI' — this supports overlap between the PPI signature and IBD-reported taxa changes. However, the source does not present a measured comparison showing the overall PPI-associated signature resembles the gut microbiome of IBD patients: its own global-composition analysis (Results, 'Meta-analysis…', PCoA fig. 3) shifts PPI users' gut microbiome toward the ORAL microbiome, and its IBD cohort (Cohort 2) was used only to test PPI effects within IBD patients, not to compare PPI users against the IBD microbiome as a whole. The 'overall signature resembling IBD' framing therefore goes beyond what this paper demonstrates. (LLM, conf=0.72)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These results confirm previous observations of biphasic effects for the Bacteroides genus dependent on the specific treatment agent(s) used9,40,41.”
§ Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma > Results > The clinical context influences abundance patterns
What the sources say
- Partly supportedcites [9] Gopalakrishnan, V. et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018). sourceExperimental — accuracy not yet measured
In the paper’s treatment-response analysis (page unavailable), higher Bacteroidales abundance was associated with shorter progression-free survival on anti-PD-1 therapy, and Bacteroides thetaiotaomicron was enriched in nonresponders. The paper does not establish biphasic effects for the Bacteroides genus that depend on the treatment agent; its comparison with CTLA-4 blockade describes a similar, not opposite, association for Bacteroidales. (LLM, conf=0.85)
- Not checked yetcites [40] Roy, S. & Trinchieri, G. Microbiota: a key orchestrator of cancer therapy. Nat. Rev. Cancer 17, 271–285 (2017). source
- Partly supportedcites [41] Vétizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079–1084 (2015). sourceExperimental — accuracy not yet measured
The paper’s Abstract reports that particular Bacteroides species support the antitumor efficacy of CTLA-4 blockade. It does not establish biphasic effects for the genus that depend on which treatment agent is used; that broader comparison is unsupported by this source. (LLM, conf=0.83)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Stratifying patients on the basis of whether they harbored higher or lower than median values of these two balances showed that patients above the median exhibited longer OS compared to patients below the median (first balance: OSHigh of 35.4 versus OSLow 28.4 months; hazard ratio (HR) of 1.669, P = 0.035; Fig. 2d; second balance: OSHigh of 37.0 versus OSLow of 26.9 months; HR of 1.792, P =”
§ Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma > Results > Cohort characteristics
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
49 more claims
Create a free account to see all 131 claims and to verify the 41 references still open.
- Probably not a substantial claim. 47
- It may state two separate claims as one. 43
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Responders tend to be enriched in Clostridia, particularly Lachnospiraceae, with SCFA-producing and fiber-degrading capacities, and pathways enriched in polyamine synthesis.189,190”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [190]
In the citing paper
“Stable taxa and functions are enriched in therapy responders across multiple cohorts, further supporting the idea that a resilient microbiome underpins effective ICI therapies.190,229”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [190]
In the citing paper
“Stable taxa and functions are enriched in therapy responders across multiple cohorts, further supporting the idea that a resilient microbiome underpins effective ICI therapies.190,229”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [190]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma > Methods > Study design and cohort description
“Fecal DNA was extracted from 1 to 14 days after sample collection using the PowerFecal DNA Isolation Kit (previously MoBio, currently Qiagen) and kept frozen until needed.”
§ Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma > Methods > Metagenomics processing
“DNA was isolated for all cohorts at King’s College London using Thermo Fisher Scientific’s MagMax Core protocols for nucleic acid purification and mechanical lysis.”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma > Results > Cohort characteristics
“PFS was defined as the time from the initial immunotherapy to disease progression or death”
§ Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma > Methods > Study design and cohort description
“PFS was defined as the time from the initial immunotherapy to disease progression.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma > Methods > Study design and cohort description
“The time between two samples was 3 or 4 weeks, depending on the treatment regimen”
§ Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma > Methods > Study design and cohort description
“with ipilimumab/nivolumab combination therapy and pembrolizumab monotherapy administered three times weekly and nivolumab monotherapy administered four times weekly.”
Citations
Cites
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · cited 3×
“For example, Thomas et al. 21 found that Eubacterium sp. AM28 29 (SGB6796 group) was associated with response in nine melanoma cohorts, four of which were not included in our study 5,9,11,36 .”
Self-citationGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 3×
“For example, Thomas et al. 21 found that Eubacterium sp. AM28 29 (SGB6796 group) was associated with response in nine melanoma cohorts, four of which were not included in our study 5,9,11,36 .”
Self-citationFormation of short chain fatty acids by the gut microbiota and their impact on human metabolism
Morrison, D. J., & Preston, T. (2016) · Gut Microbes · doi:10.1080/19490976.2015.1134082 · Cited by 3,781
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
Self-citationCaspi, R., Billington, R., Ferrer, L., Foerster, H., Fulcher, C. A., Keseler, I. M., Kothari, A., Krummenacker, M., Latendresse, M., Mueller, L. A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1164 · Cited by 3,395
Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases
Lloyd-Price, J., Arze, C., Ananthakrishnan, A. N., Schirmer, M., Avila-Pacheco, J., Poon, T. W., Andrews, E., Ajami, N. J., Bonham, K. S., Brislawn, C. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1237-9 · Cited by 3,143
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107 · cited 1×
“2a by computing it for patients from six independent melanoma cohorts 5,7–10 ,12 .”
Microbiome Datasets Are Compositional: And This Is Not Optional
Gloor, G. B., Macklaim, J. M., Pawlowsky-Glahn, V., & Egozcue, J. J. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.02224 · Cited by 3,044
Beghini, F., McIver, L. J., Blanco-Míguez, A., Dubois, L., Asnicar, F., Maharjan, S., Mailyan, A., Manghi, P., Scholz, M., Thomas, A. M., et al. (2021) · eLife · doi:10.7554/elife.65088 · Cited by 2,303
Self-citation
Cited by
Western diets and chronic diseases
Adolph, T. E., & Tilg, H. (2024) · Nature Medicine · doi:10.1038/s41591-024-03165-6 · Cited by 191
“Moreover, emerging evidence suggests that diet and modulation of the gut microbiota can be medically exploited to enhance anti-tumor therapy, a concept that warrants further controlled clinical trials 209–211 .”
Gut microbiota shapes cancer immunotherapy responses
Lei, W., Zhou, K., Lei, Y., Li, Q., & Zhu, H. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00786-8 · Cited by 194
Clinical translation of microbiome research
Gilbert, J. A., Azad, M. B., Bäckhed, F., Blaser, M. J., Byndloss, M. X., Chiu, C. Y., Chu, H., Dugas, L. R., Elinav, E., Gibbons, S. M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03615-9 · Cited by 123
“…cens and Lactobacillus gasseri were predictive of increased 12-month progression-free survival and enhanced anti-cancer immunity in a cohort of 175 patients with melanoma receiving immunotherapy, while Prevotella copri was linked to shorter progression-free survival and inflammation 67 .”
Self-citationZhu, X., Hu, M., Huang, X., Li, L., Lin, X., Shao, X., Li, J., Du, X., Zhang, X., Sun, R., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2024.12.013 · Cited by 94
Elkrief, A., Pidgeon, R., Vareki, S. M., Messaoudene, M., Castagner, B., & Routy, B. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01211-7 · Cited by 107
Metadata
- Authors
- Björk, J. R., Bolte, L. A., Maltez Thomas, A., Lee, K. A., Rossi, N., Wind, T. T., Smit, L. M., Armanini, F., Asnicar, F., Blanco-Miguez, A., Board, R., Calbet-Llopart, N., Derosa, L., Dhomen, N., Brooks, K., Harland, M., Harries, M., Lorigan, P., Manghi, P., Marais, R., Newton-Bishop, J., Nezi, L., Pinto, F., Potrony, M., Puig, S., Serra-Bellver, P., Shaw, H. M., Tamburini, S., Valpione, S., Waldron, L., Zitvogel, L., Zolfo, M., de Vries, E. G. E., Nathan, P., Fehrmann, R. S. N., Spector, T. D., Bataille, V., Segata, N., Hospers, G. A. P., & Weersma, R. K.
- Affiliations
- University Medical Center Groningen (NL)
- King's College London (GB)
- University of Trento (IT)
- Inserm (FR)
- University of Manchester (GB)
- University of Leeds (GB)
- Guy's Hospital (GB)
- European Institute of Oncology (IT)
- Instituto de Salud Carlos III (ES)
- The Christie NHS Foundation Trust (GB)
- Mount Vernon Cancer Centre (GB)
- City University of New York (US)
- Corresponding author
- Björk, Johannes R.
- Weersma, Rinse K.
- ORCID
- Björk, Johannes R.
- Bolte, Laura A.
- Maltez Thomas, Andrew
- Lee, Karla A.
- Wind, Thijs T.
- Smit, Lotte M.
- Armanini, Federica
- Asnicar, Francesco
- Blanco-Miguez, Aitor
- Derosa, Lisa
- Dhomen, Nathalie
- Brooks, Kelly
- Harland, Mark
- Harries, Mark
- Lorigan, Paul
- Manghi, Paolo
- Marais, Richard
- Nezi, Luigi
- Pinto, Federica
- Puig, Susana
- Serra-Bellver, Patricio
- Shaw, Heather M.
- Tamburini, Sabrina
- Valpione, Sara
- Waldron, Levi
- Zitvogel, Laurence
- Zolfo, Moreno
- de Vries, Elisabeth G. E.
- Nathan, Paul
- Fehrmann, Rudolf S. N.
- Spector, Tim D.
- Segata, Nicola
- Hospers, Geke A. P.
- Weersma, Rinse K.
- Venue
- Nature Medicine
- Published
- 2024-02-16
- Volume
- 30
- Issue
- 3
- Pages
- 785-796
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC10957474
- OpenAlex
- W4391883183
- Cited by
- 156
- References
- 79
- Citations by year
- 2026: 57 · 2025: 66 · 2024: 32
- FWCI
- 21.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- HAL (submittedVersion, cc-by)
- Iris (University of Trento) (submittedVersion, cc-by)
- ARCA (Università Ca' Foscari Venezia) (submittedVersion, cc-by)
- Research Explorer (The University of Manchester) (submittedVersion, cc-by)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- Amgen
- Bristol-Myers Squibb
- AstraZeneca
- World Health Organization
- Regeneron Pharmaceuticals
- Wellcome Trust (100282/Z/12/Z)
- Les Laboratories Pierre Fabre
- Seerave Foundation
- G1 Therapeutics
- European Commission (825410)
- Ministero dell’Istruzione, dell’Università e della Ricerca (RBFR13EWWI_001)
- Università degli Studi di Trento
- European Society for Medical Oncology
- Institut Gustave-Roussy
- NeraCare
- National Institutes of Health (1u01ca230551-01a1, 1U01CA230551)
- Genentech
- Chugai Pharmaceutical
- Medical Research Council (MR/MO19012/1)
- Instituto de Salud Carlos III (PI15/00716, PI15/00956)
- National Cancer Institute (1U01CA230551, U01 CA230551, R01CA230551)
- Daiichi Sankyo Europe
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Keywords
- gut microbiota, immune checkpoint blockade, advanced melanoma, progression-free survival, overall survival, immune-related adverse events, microbiome-targeted therapy, immunotherapy response
- MeSH terms
- Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Cognition, Humans, Melanoma, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma. https://app.cochat.ai/papers/10.1038/s41591-024-02803-3
- The paper
- Björk, J. R., Bolte, L. A., Maltez Thomas, A., Lee, K. A., Rossi, N., Wind, T. T., Smit, L. M., Armanini, F., Asnicar, F., Blanco-Miguez, A., Board, R., Calbet-Llopart, N., Derosa, L., Dhomen, N., Brooks, K., Harland, M., Harries, M., Lorigan, P., Manghi, P., . . . Weersma, R. K. (2024). Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma. Nature Medicine. https://doi.org/10.1038/s41591-024-02803-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.